3 results about "Vaccine research" patented technology

An adenoviral vector carrying a trichinella spiralis CLP gene, a construction method therefor, and an application thereof, relating to the technical fields of genetic engineering and recombinant viral vaccines. In order to solve the technical problem of existing trichinella spiralis vaccines being administered as a 2 to 3 dose series and failing to provide long-term efficacy, the present invention uses a trichinella spiralis CLP protein as an antigen, and integrates a gene encoding the CLP protein into an adenovirus vector by means of recombinant DNA technology, so as to obtain a recombinant adenoviral vector; the recombinant adenovirus vector is then transfected into mammalian cells and subjected to packaging and amplification processes to obtain a recombinant adenovirus, with multiple experiments then conducted to confirm the recombinant adenovirus. In addition, animal immunization experiments demonstrate that immunizing mice with recombinant adenovirus rAd5TsCLP achieves effective protection against trichinella spiralis infection. The present invention lays a foundation for subsequent trichinella spiralis vaccine research.

The present invention relates to the field of biological vaccine research and development technology, and in particular, to a VSV vector-based highly pathogenic H5 subtype avian influenza inactivated vaccine and a method for preparing same. The method comprises: using a vesicular stomatitis virus with the deletion of the surface envelope protein gene as a vector, inserting the NA gene and the HA gene of an H5 subtype highly pathogenic avian influenza virus strain between the M gene and the L gene of the vector in the form of an expression cassette, and acquiring a recombinant virus by means of rescue via reverse genetic technology; inoculating the recombinant virus into susceptible cells, culturing for replication and proliferation, and then harvesting a viral solution; inactivating the viral solution to acquire an inactivated viral solution; and adding the inactivated viral solution to a pharmaceutically or veterinarily acceptable carrier, excipient, medium, or adjuvant to acquire an inactivated vaccine. The provided H5 subtype avian influenza inactivated vaccine can induce a high hemagglutination inhibition titer of avian influenza virus on day 21 after chick immunization. The provided inactivated vaccine has good safety and immunogenicity.

The present invention provides a neutralizing monoclonal antibody 10G8 for recognizing CV-A6. Six CDR regions of the monoclonal antibody 10G8 are specifically as follows: (1) the amino acid sequence of a heavy chain CDR1 is set forth in SEQ ID NO. 1; (2) the amino acid sequence of a heavy chain CDR2 is set forth in SEQ ID NO. 2; (3) the amino acid sequence of a heavy chain CDR3 is set forth in SEQ ID NO. 3; (4) the amino acid sequence of a light chain CDR1 is set forth in SEQ ID NO. 4; (5) the amino acid sequence of a light chain CDR2 is set forth in SEQ ID NO. 5; and (6) the amino acid sequence of a light chain CDR3 is set forth in SEQ ID NO. 6. The monoclonal antibody 10G8 provided in the present invention can recognize the CV-A6 virus, has neutralizing activity, has a 100% protection rate in mice, and is of great significance for the treatment of diseases caused by the CV-A6 pathogen and for vaccine research.